ex.VAT:
VAT:
inc.VAT:

Summer 2022 special
Friday, July 8, 2022Regulation

Kojic acid: the SCCS revises its final Opinion

Kojic acid : le CSSC révise son Opinion finale

Following the mandate given by the European Commission to the SCCS in the context of the safety assessment of substances with potential endocrine disrupting properties, the Scientific Committee published its final Opinion on Kojic Acid in March 2022. A corrigendum has just been released.

Reading time
~ 3 minutes

Background

Kojic Acid (CAS No.501-30-4, EC No.207-922-4) is used as a skin lightening/whitening or depigmenting agent in cosmetic products.
The Scientific Committee published its final Opinion in March 2022 and indicated that it was of the opinion that the 1% concentration of Kojic acid was not safe for the intended use in cosmetic products and recommended a maximum concentration of 0.7% for use as a whitening agent.

For an exhaustive background information, see the articles
Endocrine disruptors: 2nd call for data from the European Commission, CosmeticOBS, 22 February 2021
Endocrine disruptors: 5 new requests for SCCS Opinions, CosmeticOBS, 15 March 2021
Kojic Acid: the SCCS preliminary Opinion, CosmeticOBS, 15 November 2021
Kojic Acid: the SCCS final Opinion, CosmeticOBS, 21 March 2022

This Final Opinion was subject to a corrigendum adopted by the SCCS on 10 June 2022. It includes changes in the following sections: calculation of the systemic exposure dose, safety assessment and conclusion.

The new final Opinion

1. In light of the data provided and taking under consideration the concerns related to potential endocrine disrupting properties of Kojic acid, does the SCCS consider Kojic Acid safe when used in cosmetic products …

This content is only available to subscribersPREMIUM, PRO, STARTUPandTPE

Already subscribed?Log in

Discover our subscriptions

CosmeticOBS' PRO services

RegulationOther articles

884results